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ABSTRACT
Human purine de novo synthesis pathway contains
several multi-functional enzymes, one of which,
tri-functional GART, contains three enzymatic
activities in a single polypeptide chain. We have
solved structures of two domains bearing separate
catalytic functions: glycinamide ribonucleotide
synthetase and aminoimidazole ribonucleotide
synthetase. Structures are compared with those of
homologous enzymes from prokaryotes and
analyzed in terms of the catalytic mechanism. We
also report small angle X-ray scattering models for
the full-length protein. These models are consistent
with the enzyme forming a dimer through the middle
domain. The protein has an approximate seesaw
geometry where terminal enzyme units display
high mobility owing to flexible linker segments.
This resilient seesaw shape may facilitate internal
substrate/product transfer or forwarding to other
enzymes in the pathway.
INTRODUCTION
The biosynthesis of nucleotides is a crucial process for the
production of building blocks for RNA and DNA, as well
as to provide nucleotides for additional cellular processes
where they, for example, serve as energy carriers or sig-
naling molecules. In the cell, de novo synthesis pathways
where nucleotides are synthesized from small metabolites,
work in coordination with salvage pathways, where nu-
cleotides are reversibly regenerated from nucleosides and
nucleobases, to control the intracellular nucleotide pools.
Due to the central role of nucleotides in the human cell,
enzymes of the nucleotide metabolism constitute potential
anti-proliferative drug targets for the treatment of
e.g. cancer or autoimmune diseases (1). Furthermore,
enzymes of the nucleotide metabolism in pathogens also
provide interesting targets for the development of anti-
biotics (2). Genetic variations in the human nucleotide
metabolism are also known to cause several disorders
including gout and Lech–Nyhan syndrome (3).
In the de novo pathways for purine synthesis,
phosphoribosyl pyrophosphate is converted to inosine
monophosphate in 10 steps (4). In humans, these
steps are catalyzed by six different enzymes; three
monofunctional, two bifunctional and one tri-functional
enzyme (5). Although many of the enzymes of the nucleo-
tide metabolism are well characterized from prokaryotic
sources the eukaryotic counterparts are less well
characterized. In our current effort to systematically char-
acterize the structure and mechanism of the enzymes of
the human nucleotide metabolism (see http://sgc.ki
.se/structures.html) we have determined structures of com-
ponents of the tri-functional human GART (HsGART)
(108kDa, 1010 amino acids). HsGART is composed
of three enzyme units: glycinamide ribonucleotide
synthetase (GARS, PurD, E.C. 6.3.4.13), aminoimidazole
ribonucleotide synthetase (AIRS, PurM, E.C. 6.3.3.1) and
glycinamide ribonucleotide transformylase (GARTfase,
PurN, E.C. 2.1.2.2.). HsGART thus catalyzes steps 2, 3
and 5 of the de novo purine synthesis pathway (Figure 1).
The N-terminal enzyme unit GARS catalyses the
second step of the purine pathway and uses phosphori-
bosylamine (PRA), the product of PRPP
amidotransferase (PPAT, PurF, E.C. 2.4.2.14), as well as
ATP and glycine to make glycinamide ribonucleotide
(GAR), ADP and Pi (Figure 1). The C-terminal
GARTfase unit carries out the third-reaction step in the
synthesis by forming N-formylglycinamide ribonucleotide
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a cofactor (Figure 1). Finally the middle domain of
HsGART, AIRS, uses formylglycinamidine
ribonucleotide (FGAM) and ATP to form
aminoimidazole ribonucleotide (AIR), ADP and Pi
(Figure 1). The central fourth step of the purine
pathway is performed by phosphoribosyl formylgly-
cineamide amidotransferase (FGARAT, purL,
E.C.6.3.5.3), which is encoded by a separate gene
(purL) (1).
Notably, PRA, the substrate of GARS, is very unstable
and hydrolyzes spontaneously to ribose 5-phosphate and
has a half-life of only 5s at 37 C (6). PRA has therefore
been suggested to be transferred directly from PPAT to
GARS (7). However, interactions between these protein
components are believed to be transient as no direct inter-
actions have been observed (6).
Being an enzyme in the core nucleotide metabolism,
HsGART is a potential target for anti-proliferative
drugs. The C-terminal GARTfase domain uses folate as
a cofactor, and inhibitors of folate-dependent enzymes
have been demonstrated to have anti-tumor activity
in vivo (8). HsGART is localized to chromosome 21 (9)
and trisomy of this chromosome is observed in Down
syndrome. Individuals with Down syndrome have also
been shown to have increased levels of serum purines
that may be caused by the overexpression of HsGART
(10).
Here, we present the structures of two functional
domains of HsGART: GARS and AIRS. Together with
the previous structures of the GARTfase domain of
HsGART (11–12), this completes the structural character-
ization of the individual functional units of HsGART,
thereby providing a structural framework for understand-
ing substrate speciﬁcity and catalytic mechanism, as well
as for structure-based drug design. Furthermore, we
present the low-resolution structure of the complete
tri-functional enzyme obtained by combining small angle
X-ray scattering (SAXS) data with the high-resolution
crystal structures, revealing the overall architecture of
the protein. The latter analysis might also have implica-
tions for HsGART’s role as a potential core unit of
the recently discovered multi-enzyme complex, ‘the
purinosome’, which is assembled in response to purine
levels in the cell (13).
METHODS
Cloning
The clone for the GART gene was obtained from National
Institute of Health Mammalian Gene Collection (MGC;
accession no. BC107712). The sequences encoding
residues 1–430 (GARS) and 1–1003 (GARS–AIRS–
GARTfase) were ampliﬁed by PCR and inserted into
pNIC28-Bsa4 vector by ligation independent cloning.
Constructs include an N-terminal tag containing a 6-His
sequence (MHHHHHHSSGVDLGTENLYFQSM). For
expression, the pNIC28-Bsa4 vector containing the insert
was transformed into Escherichea coli BL21(DE3) gold
pRARE2 strain.
Protein expression
GARS. One hundred and ﬁfty milliliter of LB supple-
mented with 8g/l glycerol, 50mg/ml kanamycin and
34mg/ml and chloramphenicol was inoculated and grown
at 37 C overnight. Of the overnight cultures, 120ml were
used to inoculate 3l (4 750ml) of Terriﬁc Broth (TB)
supplemented with 8g/l glycerol and antibiotics. Cells
were grown in TunAir ﬂasks at 37 C until OD600
reached 1.5. Cultivations were cooled down to 18 C and
protein expression was induced by addition of 0.5mM
IPTG at OD600 of 2.5 and the growth was allowed to
continue overnight. Cells were harvested (OD600 15.2) by
centrifugation (5500g, 20min, 4 C). The resulting pellet
(93.8g wet cell weight) was frozen at  80 C.
GARS–AIRS–GARTfase. One hundred and ﬁfty milliliter
LB media supplemented with glycerol and antibiotics was
inoculated and grown overnight at 37 C. TB media (3l in
4 750ml) supplemented with glycerol, antibiotics and
200ml BREOX FMT 30 anti-foam solution (Cognis
Performance Chemicals UK Ltd) was inoculated with
80ml of the overnight cultures. Cells were grown at
37 C and when OD600 reached the value of 2 the tempera-
ture was cooled down to 18 C and the culture induced
with 0.5mM IPTG. Protein expression was continued
overnight. The cells (106g) were harvested by centrifuga-
tion (4400g, 10min, 4 C) and frozen.
Protein puriﬁcation
GARS. Cells were thawed and resuspended in lysis buffer
(0.5ml/g of cells) containing 100mM HEPES pH 8.0,
500mM NaCl, 10% glycerol, 10mM imidazole and
0.5mM TCEP. Protease inhibitor cocktail (one tablet of
complete, EDTA-free, Roche applied Science),  0.25mg
of lysozyme (Sigma) and 1000U of benzonase (Merc) was
added and the sample was sonicated using Sonics
VibraCell at 80% amplitude for 3min (pulsed 4s on, 4s
off). The sample was centrifuged for 60min at 34000g.
Soluble fraction was decanted and ﬁltered through a
0.45mm ﬁlter. The puriﬁcation was conducted on an
A ¨ KTA Prime (GE Healthcare). A HisTrap HP 5ml
Figure 1. Steps 2–5 of the purine de novo synthesis pathway. Enzymes and intermediates are named as deﬁned in the text.
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binding buffer (20mM HEPES pH 7.5, 10mM imidazole,
500mM NaCl, 10% glycerol, 0.5mM TCEP). The sample
was loaded and the column was supplemented with buffer
containing 25mM imidazole. The protein was eluted with
buffer supplemented with 500mM imidazole. The second
puriﬁcation step, gel-ﬁltration, was conducted on a
Superdex 200 High Load 16/60 Prep Grade (GF), (GE
Healthcare) using a gel ﬁltration buffer containing
20mM HEPES, pH 7.5, 300mM NaCl, 10% glycerol,
0.5mM TCEP. The protein eluted in a single peak from
the GF column. Fractions containing monomeric protein
were pooled and the protein was concentrated with
Vivaspin (Sartorius Stedim Biotech) with a MWCO of
10kDa to 21.5mg/ml in a volume of 0.72ml. Small
aliquots were ﬂash frozen in liquid nitrogen and stored
at  80 C.
GARS–AIRS–GARTfase. Lysis buffer (1ml/g cell pellet)
supplemented with protease inhibitor cocktail,  0.25mg
of lysozyme and 1000U of benzonase was added to the
thawed pellet prior to sonication. The sample was
centrifuged; the soluble fraction was decanted and
ﬁltered. Protein puriﬁcation was carried out on an
A ¨ KTAxpress system (GE Healthcare) operated by
UNICORN. Prior to puriﬁcation, columns were
equilibrated with binding buffer (1ml HiTrap Chelating
HP, GE Healthcare) and gel ﬁltration buffer (Superdex
200). The protein sample was loaded on the HiTrap
Chelating column and washed with binding buffer
followed by a wash with buffer supplemented with
25mM imidazole. Bound protein was eluted from the
IMAC columns with buffer supplemented with 500mM
imidazole and loaded onto a gel ﬁltration column.
Fractions containing GARS–AIRS–GART were pooled
and fresh TCEP was added to the ﬁnal concentration of
2mM. Concentration was performed using a Vivaspin to a
concentration of 12.4mg/ml in a volume of 0.5ml and
ﬂash frozen.
Crystallization, data collection and structure
determination
GARS. Crystals were obtained by hanging drop vapor
diffusion. Protein solution (15.7mg/ml, 1ml) containing
also 4mM ATP and 4mM glycine was mixed with pre-
cipitant solution (1ml) containing 16% PEG 3350,
100mM Bis–Tris pH 5.2 and 300mM lithium sulfate.
The drops were equilibrated at 20 C over 500ml of well
solution. A crystal was dipped into a cryo solution
(100mM Bis–Tris pH 5.2, 300mM lithium sulfate, 17%
PEG-3350, 200mM NaCl and 20% glycerol) and
ﬂash-frozen in liquid nitrogen. Data were collected at
the ESRF beamline ID14-2 and processed with XDS
(14) (Table 1).
For molecular replacement, protein data bank (PDB)
entry 1GSO was trimmed according to the sequence align-
ment using MrBUMP (15) and CHAINSAW (16). The
edited model was used as an input for MOLREP (17),
which located two molecules in the asymmetric unit.
Model building and reﬁnement were done with COOT
(18) and REFMAC5 (19), respectively. TLS reﬁnement
with three groups per monomer was carried out with the
groups selected according to the suggestion of TLS
motion determination server (20–21) (Table 1). The coord-
inates and structure factors are available from the PDB
under accession ID 2QK4.
AIRS. Crystals were obtained using the hanging drop
vapor diffusion method. Notably, 0.2mg/ml of chymo-
trypsin was added to the protein solution prior to crystal-
lization. One microliter of protein solution (12.4mg/ml)
was mixed with 1ml of well solution containing 0.1M
Bis–Tris pH 5.2, 27% PEG 3350 and 0.2M ammonium
sulfate. Plate was incubated at 20 C and crystals appeared
in a couple of days. A crystal was dipped into a cryo
solution containing 0.1M Bis–Tris pH 5.2, 25% PEG
3350 and 200mM ammonium sulfate, 200mM NaCl and
20% glycerol before ﬂash frozen in liquid nitrogen. Data
collection was carried out at BESSY BL14-1 and pro-
cessed with XDS (14) (Table 1).
The structure was solved with molecular replacement
using PHASER (22) with the PDB entry 1CLI as a
search model. Model building and reﬁnement were done
Table 1. Data and reﬁnement statistics
GARS AIRS
Beamline ID14-2 (ESRF) BL 14.1 (BESSY)
Wavelength (A ˚ ) 0.93300 1.00
Space group P21 P21212
Resolution (A ˚ ) 20–2.45 (2.50–2.45) 15–2.10 (2.15–2.10)
Cell dimensions
a, b, c (A ˚ ) 70.3, 79.8, 113.9 80.7, 81.0, 98.3
  ( ) 104.1
Resolution (A ˚ ) 2.45 2.1
Rmerge
a 0.049 (0.341) 0.08 (0.39)
I/s(I) 22.15 (3.94) 28.70 (8.06)
Completeness (%) 99.2 (91.7) 99.6 (100)
Redundancy 5.6 (3.4) 14.8 (14.9)
Reﬁnement
Number of reﬂections 42544 38171
Rwork
b/Rfree
c 0.174/0.221 0.194/0.240
No. of atoms
Protein 6262 4695
Water 111 170
Other 98 15
B-factors (A ˚ 2)
Protein 60.3 32.9
Water 51.6 34.4
Other 73.9 33.2
RMSD
Bond lengths (A ˚ ) 0.014 0.014
Bond angles ( ) 1.546 1.477
Ramachandran plot (%)
d
Favored regions 95.79 98.86
Additionally allowed regions 4.09 1.14
Values for the highest resolution shell are shown in parentheses.
aRmerge=i WIi hIiW/ hIi, where I is an individual intensity measure-
ment and hIi is the average intensity for this reﬂection with summation
over all data.
bRwork is deﬁned as WWFobsW WFcalcWW/ WFobsW, where Fobs and Fcalc are
observed and calculated structure-factor amplitudes, respectively.
cRfree is the R-factor for the test set (5% of the data).
dAccording to molprobity (44).
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protein molecule was used in the reﬁnement (Table 1). The
structure revealed that N- and C-terminal domains were
removed by chymotrypsin and only the AIRS domain was
crystallized. According to mass spectrometry from the
chymotrypsin treated protein the size of this domain was
34968 Da and the most probable sequence for the segment
consisted of residues 467–794. The coordinates and struc-
ture factors are published in the PDB under accession id
2V9Y.
SAXS and rigid-body modeling
Aliquotes of the full-length HsGART were prepared at
concentrations between 0.5 and 7mg/ml in the gel ﬁltra-
tion buffer. Synchrotron SAXS experiments were per-
formed at station 2.1 of the SRS Daresbury, UK
according to standard procedures (23) using
sample-to-detector distances of 1m and 4.5m covering a
momentum transfer range of 0.008A ˚  1<q<0.75A ˚  1 with
q=4 p sin()/l (where 2 is the scattering angle and l
the X-ray wavelength of 1.54A ˚ ). The background signal
was deducted by means of the scattering from the buffer
alone. Data processing was carried out along with previ-
ously published methods (24) including the calculation of
the radius of gyration and maximum molecular dimen-
sion. Low-resolution ab initio shapes were restored with
the program GASBOR (25) using a 2-fold symmetry con-
straint. Due to the expected conformational plasticity of
the dimeric full-length construct, ab initio shapes were
used to scrutinize possible domain arrangements as
starting condition for rigid-body modeling that was sub-
sequently carried out with the program BUNCH (26) to ﬁt
the experimental scattering data. In view of the known
high-resolution structures for all three enzyme domains
rigid-body modeling offers an obvious advantage over
shape reconstruction so as to adequately explore the con-
formational space of domain positions as well as of the
extended and mobile linker segments. Speciﬁcally, the fol-
lowing assumptions were made during rigid-body
modeling: (i) AIRS forms a dimer similar to the crystal-
lographic one in the full-length enzyme. (ii) The
N-terminal helix of AIRS, 441–463, was modeled accord-
ing to the EcAIRS structure and the ﬂexible G1 loop was
not modeled. (iii) Residues 787–792 were modeled rather
than using their conformation observed in the AIRS
crystal structure as these result from crystallographic
contacts, which most likely do not represent a biologically
relevant conformation.
Structure analysis and ﬁgures
Superpositions used in the text and ﬁgures were made
using the SSM superposition algorithm in COOT
(18,27). Structural representations were made using
Pymol (28). Electrostatic potential was calculated with
APBS (29) using solvent and protein dielectric constants
80 and 2, respectively. Docking was done using GOLD 3.2
through the Hermes interface and the docking wizard (30).
Goldscore was used to rank the docking results.
RESULTS AND DISCUSSION
Structure of GARS
Overall structure. The structure of GARS belongs to the
superfamily of ATP-grasp proteins (31). The N-terminal
GARS unit of HsGART has an  / -fold consisting of four
structural sub-domains similar as described by Wang et al.
(7) (Figures 2A and 3A) for the bacterial homolog, E. coli
GARS (EcGARS). The domains are named N
(N-terminal), B, A and C (C-terminal). Domains N, A
and C form the core of the enzyme with B being located
towards the periphery. HsGARS was co-crystallized with
ATP, which is bound between the A and B domains in the
structure. The co-substrate glycine was also included in
the crystallization, but was not found in the structure,
most likely due to crystallization at low pH. The asym-
metric unit of the crystal contains two monomers, where
residues 0–429 and 0–430 were modeled in the electron
density for monomers A and B, respectively. Both
monomer models are missing two short loops in the
B-domain (A: 153–155 and 178–184; B: 154–156 and
179–182).
ATP binding. The closest structural homolog of GARS
is EcGARS (7), which shares 51% sequence identity and
superimposes with a RMSD value of 1.7A ˚ for 381Ca
atoms. The B-domains of GARS and EcGARS are
however in a signiﬁcantly different conformation relative
to the core structure (Figure 3A). When the B-domain
(residues 123–191) is omitted in the structural alignment,
the ﬁt is better with a RMSD value of 1.2A ˚ for 347Ca’s
(Figure 3A). Also the B-domains by themselves superim-
pose well (RMSD 1.6A ˚ ). The largest movements of the
B-domain are as extensive as 16A ˚ or an angle of 27 
between EcGARS residues Gly178, Phe189 and Gly178.
All GARS enzyme structures reveal B-domains in a dif-
ferent orientation with respect to the core enzyme most
likely due to crystal packing effects. In the structures of
GARS from Geobacillus kaustophilus (GkGARS; 2YRW,
2YRX, 2YS6 and 2YS7) and Aquifex aeolicus (AaGARS;
2YW2, 2YYA), where ATP is bound, nucleotide binding
does not induce large changes in the orientation of the
B domain. In another enzyme of the ATP-grasp family,
PurK or AIRC of E. coli, ADP binding was seen to induce
a small 2.5A ˚ movement of the B-domain (32). This dem-
onstrates the mobility of the B-domain in GARS enzymes.
ATP binding alone does not appear to stabilize the
catalytic conformation as non-competent conformations
have been observed in AaGARS (2YW2) and reported
here in GARS.
In GARS, hydrophobic side chains align the
adenosine-binding site and adenosine also makes
conserved hydrogen bonds to the backbone carbonyl of
Glu190, backbone amide of Leu193 and to carboxyl group
of Glu191 (Figure 3B). Glu197 is coordinating the ribose
by hydrogen bonding to the hydroxyl groups. The phos-
phates of ATP, interacting with Arg220 and Asn229 of
GARS (Figure 3B), are less well coordinated as the
B-factors of the ATP vary from 40–65 A ˚ 2 for the
adenine moiety to 90–110 A ˚ 2 for the phosphate atoms.
We also crystallized GARS in the presence of Mg
2+
Nucleic Acids Research, 2010, Vol.38, No. 20 7311excess, but this did not result in a more ordered structure
of the ATP molecule (data not shown). In the light of the
reported ordered, sequential mechanism of GARS, with
PRA binding ﬁrst, then ATP and glycine (33), the ﬂexibil-
ity of the ATP phosphates suggest that the ATP binding
seen in the GARS crystal structure represents ATP in a
‘waiting position’.
Binding of PRA. We have not been able to determine the
structure of GARS with either its substrate PRA or
glycine, but based on homologous structures we propose
binding sites for these substrates in the active site of
GARS (Figure 3C and discussions below). The closest
structural homolog of GARS, after the prokaryotic
GARS enzymes, was found through a DALI search (34).
This is the E. coli PurT-encoded glycinamide
ribonucleotide transformylase (EcGART) (PDB ID.
1EZ1; (35). EcGART catalyses an alternative formylation
reaction utilizing ATP and formate and proceeds through
a formyl phosphate intermediate (35). EcGART was
solved in complex with Mg
2+, AMPPNP and GAR—
the product of GARS (35). The ATP conformation
and the catalytic core were shown to be similar to the
one in D-alanine–D-alanine ligase, although the acceptor
substrates are quite different. Structural comparison
of GARS with EcGART, which use the structurally
most similar substrate, might indicate how a ternary
substrate complex is interacting in GARS and thereby
shed light on the binding mode of PRA and glycine
(Figure 3C).
Superposition of the structures reveals that in GARS,
the phosphates of ATP are in a different position
compared to the ternary-like complex of EcGART, and
have swung out of the active site as discussed above. Due
to similarities in the catalytic mechanisms, it is however
plausible that ATP in the ternary complex of GARS, will
be in a similar conformation as ATP in a ternary-like
complex of EcGART, despite all residues coordinating
Mg
2+ ions being non-conserved residues (Glu267 of
EcGART replaced by Gly276). This also suggests that
GAR, the product of GARS and substrate of EcGART,
will bind in the same pocket in both enzymes, providing a
similar geometric relationship to ATP in a ternary
complex. Although the pockets appear to have similar
size and topology in the two enzymes, it is likely, that
GAR (and PRA) will bind to GARS in a somewhat dif-
ferent manner than in EcGART. Between GARS and
EcGART only Arg385/363, which binds to the glycine
moiety of GAR in EcGART, is conserved (Figure 3C).
The distribution of positively charged residues in the
binding pocket appears reversed. At the site where the
phosphate of GAR is binding in EcGART there are
three positively charged residues Lys355, Arg362 and
Arg363, whereas in GARS there is only one (Arg385).
On the opposite side of the pocket, EcGART has one
positively charged residue, Arg283, while in GARS
Arg13, Arg292 and a positive dipole of the short helix
75–80 are found. A sulfate ion is bound in the GARS
structure between Arg13, Arg292 and capping the short
helix. Sulfate or phosphate ions are found at this site also
Figure 2. Schematic presentation of crystal structures of the HsGART domains. (A) GARS in complex with ATP. (B) Ternary complex of
GARTfase with 10-(triﬂuoroacetyl) 5,10-dideazaacyclic-5,6,7,8-tetrahydrofolic acid and substrate glycinamide ribonucleotide (PDB ID. 1RBY).
(C) Dimeric structure of AIRS.
7312 Nucleic Acids Research, 2010, Vol.38, No. 20Figure 3. Substrate binding to GARS. (A) Conformational change in GARS induced by binding of ATP. Cartoon model of GARS is shown in slate
blue together with the ATP molecule, glycerol and sulfate ion. Comparison with EcGARS crystallized in apo form reveals the movement of Domain
B. Domains of EcGARS are colored blue (N), green (B), yellow (A) and red (C). (B) ATP-binding cleft in GARS. Hydrogen bonds between ATP
and residues are shown. Electrostatic potential is mapped from solvent accessible surface and is shown from  4 kT (red) to +4 kT (blue).
(C) Comparison of GARS with EcGART (orange) crystallized with AMPNP, Mg
2+ and GAR (35). Modeled position of PRA is shown in
white. Active site of GARS contains a sulfate ion and a glycerol molecule in addition to ATP. Glycine observed in GkGARS structures (2YS6)
is shown with white carbon atoms. Ligands in the active sites are shown as ball-and-stick models and Mg
2+-ions as grey spheres. Rotamer change in
Asp295 is indicated as white alternative conformation.
Nucleic Acids Research, 2010, Vol.38, No. 20 7313in other crystal structures of GARS enzymes. A bound
glycerol molecule is also observed near the PRA-binding
site of GARS, close to the phosphate group of GAR in
EcGART (Figure 3A and C). Notably, in some crystal
structures of homologous proteins (Thermus thermophilus
GARS-2IP4 and GkGARS-2YRX) sulfate or phosphate
ions are present at this site and thus despite of the presence
of glycerol in the GARS structure, it is tempting to suggest
that this could form the binding site for the PRA phos-
phate. Only a 2A ˚ shift in the phosphate position seen in
GAR of EcGART would be required to enable hydrogen
bond formations with the backbone amides and Arg363
(Figure 3C). The key residue for coordinating GAR in
EcGART, Arg362, is not conserved in GARS enzymes.
The second sulfate-binding site found in the human
GARS structure may therefore represent the binding site
of the product phosphate. Glycine binding Arg292 may
furthermore stabilize the acyl phosphate intermediate as
has been suggested previously (35).
This substrate binding mode would require only small
changes in GARS, as compared with EcGART
(Figure 3C). The potential candidate residue orienting
the ribosyl of PRA, similarly to Glu82 in EcGART,
would be Glu14. These residues reside in different
secondary-structure elements showing a complementary
change from Glu to Gly and vice versa. If the
glycerol-binding site reﬂects the PRA phosphate site
then some of the interactions with the ribose moiety
may be mediated by water molecules.
Glycine binding. Studies of EcGARS have indicated that
the enzyme is very speciﬁc for glycine (33). Because of the
sequential binding of substrate molecules, with glycine
being last in the sequence, it appears that ATP as well
as PRA might contribute to the glycine-binding site. It
has been proposed that glycine would bind directly
in-between ATP and PRA (36). Glycine was indeed
found between ATP and PRA sites in one of the
GkGARS structures (2YS6) making hydrogen bonds
with the Asp295 carboxylate group (GARS numbering),
Asp217, Glu297 and Arg292 (Figure 3C), which are
conserved in GARS. A binding site for glycine between
ATP and PRA would be in agreement with the mechanism
proceeding via an acyl phosphate intermediate, which
could then react with PRA on the other side of glycine
(33). In the structure of GARS, there is some residual
density at the glycine-binding site, albeit this density
could not be unambiguously interpreted as a glycine. In
D-alanine–D-alanine ligase the binding site for alanine
overlaps with the proposed glycine-binding site in
GARS (37).
Three binding sites—implications of structures for
catalysis. Residues and structures implicated in the cata-
lytic site of GARS are shown in Figure 3C. The initial step
of the reaction is the phosphoryl transfer from ATP to
glycine. Glycine is coordinated by two conserved acidic
residues Asp217 and Glu297 as well as backbone
carboxyl of Arg292 (2YS6). This places glycine appropri-
ately to perform an in-line nucleophilic attack on the
g-phosphate of ATP (Figure 3C). We proposed that the
ATP seen in GARS is in a waiting position while in e.g.
EcGART structure (35), ATP binds in a catalytically more
relevant orientation. It should be noted that the B-loop
interacting with the g-phosphate of ATP (2YW2, 2YYA)
is missing in most of the structures and that the B-loop
sequence, GLAAGK, is conserved in all the GARS
enzymes discussed here. The negatively charged transition
state of this ﬁrst reaction step is likely to be stabilized by a
Mg
2+ ion, backbone amides of the B-loop and possibly
Lys219.
In the second part of the reaction, the reactive amine of
PRA should reside closer to the intermediate than in the
model presented in Figure 3C. A conformational change is
thus required prior or during the reaction. The
acylphosphate intermediate could be stabilized by
Arg292 and Arg13 that form a sulfate-binding site in the
GARS structure. Asp295 also needs a rotamer change
upon substrate binding. This would place Asp295 appro-
priately to bind to the amine of PRA and to interact with
Arg13. This change would enable it to act as a general
base similarily to the Asp286–Arg363 pair as suggested
for EcGARS (35).
Crystal structure of AIRS
Overall structure. Several attempts of making a soluble
construct for the AIRS domain had failed. Instead a
longer construct (1–1003) containing all three enzyme
components was crystallized in the presence of chymo-
trypsin and during crystallization the N- and C-terminal
domains were separated and only the AIRS domain
crystallized (38). The monomer A in the asymmetric unit
has better electron density and the model consists of
residues 475–792, while in monomer B residues 475–785
were modeled (Figure 2B). A ﬂexible loop corresponding
to residues 770–773 does not have electron density and
was not modeled in either subunit. The monomer of
AIRS can be divided into two domains, Domains A
(475–590) and B (603–792), as described for the E. coli
enzyme (EcAIRS) (39). A dimer interface is formed by a
4-stranded b-sheet from Domain A of each subunit
(Figure 2). According to DALI (34) the most similar struc-
ture to the human AIRS is EcAIRS giving a RMSD of
1.3A ˚ for 294 Ca superimposed. The sequence identity
between human AIRS domain and E. coli AIRS is 47%.
In the crystal structure of AIRS, we observe similar di-
merization through the b-sheets as seen in EcAIRS (39).
A glycine rich loop (GGLGGFGA; G1) in the EcAIRS
is believed to be involved in the binding of ATP (39). This
loop is not visible in the AIRS structure electron density
(Figure 4A). A second-glycine-rich region (GVGTK; G2)
is located in a deep cleft near the sulfate-binding site and
has been suggested to be involved in binding of the
FGAM (39). The AIRS structures belong to the PurM
superfamily, as do the structure of formylglycineamide
ribonucleotide amidotransferase from Thermotoga
maritime (TmFGARAT) (40). The members of the
PurM superfamily are believed to share similar catalytic
mechanism via iminophosphate intermediates (39–40).
The structure of TmFGARAT has been solved in sev-
eral complexes, e.g. in presence of an ATP analog
7314 Nucleic Acids Research, 2010, Vol.38, No. 20(AMPPCP; 2HRY) and formylglycinamide ribonucleotide
(FGAR and AMPPCP; 2HS4) (40). AIRS and
TmFGARAT have a sequence identity of 22% spanning
residues 520–795. When superposed the structures align
well yielding a RMSD value of only 2.1A ˚ per 200 Ca
atoms and 2.9A ˚ (433 Ca atoms) in the case of dimeric
AIRS. Although enzymes catalyze different reactions the
comparison of the structures can provide some clues about
ATP and FGAM binding in AIRS.
Binding of FGAM. Three sulfate ions are bound to the
two AIRS monomers in the asymmetric unit. S1 sulfate
ions are situated between the two domains near the G2
motif (Figure 4A). S2 sulfate is bound in proximity to
positively charged residues Arg604, His674 and Lys676
on the protein surface only in subunit B and it is
participating in the crystal contacts. Sulfate S1 is found
in both the AIRS and EcAIRS structures (39) with a
sulfur–sulfur distance of only 0.6A ˚ (Figure 4A). As both
FGAM and ATP contain phosphate, sulfate sites could
correspond to either of their binding sites. It is however
more likely that sulfate S1 binds at the FGAM-binding
site, because of its proximity to the FGAR-binding site in
TmFGARAT (Figure 4B). In the superimposed model,
sulfate ion S1 is situated 5A ˚ away from the phosphate
of FGAR in comparison to 10A ˚ for the g-phosphate of
the ATP analog (Figure 4B). The G2 motif predicted to
form the FGAM-binding site is lining the FGAR-binding
Figure 4. Active-site cavity at AIRS dimer interface. (A) Comparison of AIRS and EcAIRS structures. Monomers of AIRS are shown in blue and
magenta and EcAIRS is white. Glycine rich motifs G1 and G2 are colored red and orange, respectively. Conserved M1 motif thought to form
ATP-binding site is in cyan. The S1 sulfate located close to the G2 motif is shown. The N-terminal helix of EcAIRS used in the rigid body ﬁtting of
SAXS data is labeled with ‘N’. (B) Potential binding mode of substrate to AIRS. Superpositioned FGAR and AMPPcP-Mg of TmFGARAT are
shown in grey on top of the AIRS structure with monomer A colored from blue to read, monomer B in magenta and sulfate in white. Docking pose
of FGAR to the AIRS structure is shown as a ball-and-stick model.
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compared (Figure 4B). The long distance between the
FGAR phosphate and the sulfate ion indicates a different
binding mode of FGAM in AIRS (Figure 4B). Upon
direct superposition of TmFGARAT, there are clashes
between FGAR and AIRS enzyme that make the same
binding mode unlikely in AIRS. In TmFGARAT there
are two conserved histidines shown to be important for
catalysis (40). Potential residues that could be involved in
the stabilization of reaction intermediates are the
conserved His620 and His680, different from those of
TmFGARAT. They are lining the nearby pocket that is
covered by Met519 in the AIRS crystal structure
(Figure 4B). It could be possible that after the phosphoryl
transfer reaction these two histidines could have a role in
the following cyclization as has been suggested (40). This
would require a conformational change making them
available to the intermediate. It is possible that the con-
formation of the active site is affected by low pH of
5.5 used in the crystallization and the conformation seen
in the crystal is not catalytically competent. This could
be caused by protonation of His680. This pH
induced change would be similar to the one seen in
GARTfase (12).
ATP-binding mode and implications for the
mechanism. The PurM superfamily contains a conserved
motif M1 (Dx(4)GAxP) which forms a helix-turn-strand
structure (Figure 4A) (39). This motif is believed to par-
ticipate in ATP and magnesium binding (39–40).
Comparison of the AMPPcP TmFGARAT complex and
HsAIRS and EcAIRS structures gives a picture of the
ATP-binding mode in AIRS enzymes. Residues involved
in magnesium binding and residues making up the hydro-
phobic surrounding of the adenine moiety are strongly
conserved (40). The different complexes of TmFGARAT
and nucleotides show similar positions of a- and
b-phosphates while the g-phosphates are taking different
conformations. Most interactions with the phosphate
moiety of AMPPcP are from magnesium ions and
water, thus making it harder to predict the binding.
Therefore, while the adenosine-binding motif is likely the
same in AIRS, EcAIRS and TmFGARAT, the inter-
actions with the phosphate groups may be somewhat dif-
ferent. The N-terminus of EcAIRS contains a glycine rich
G1 loop, which is believed to be involved in the ATP
binding (41). This loop is not visible in the AIRS structure
but when AIRS, EcAIRS and TmFGARAT are
superimposed, it is evident that the G1 loop is positioned
close to the ATP-binding site of TmFGARAT and thus
this loop may be important in binding of ATP also in
AIRS—it may become ordered upon ATP binding
(Figure 4A).
Quaternary structure
The crystal structures reported here together with those
previously published (11–12) complete the structural
scaffold of human tri-functional GART: high-resolution
structures of all individual globular domains from
HsGART are now available. In addition, we also
produced a close to full-length construct of HsGART,
which we did not succeed in crystallizing in an intact
form. However, we performed SAXS experiments on
this full-length enzyme in solution in order to determine
its overall conformation and to visualize relative arrange-
ments of domains.
The conformational space taken up by full-length
HsGART as derived from SAXS is shown in Figure 5.
The experimental proﬁle (see Supplementary Figure S1)
characterizes a dimeric enzyme with a maximum molecu-
lar dimension of 205±10A ˚ and a radius of gyration of
64.1±0.5A ˚ . Considering that a compact macromolecule
of similar mass (220kDa) would be expected to yield a
radius of gyration of  40A ˚ (42), the dimer of full-length
HsGART can only be described by an extended conform-
ation. This feature is strongly linked with the mobile and/
or unstructured nature of polypeptide segments connect-
ing the globular enzyme domains. The conformational
ﬂexibility has been presented by depicting multiple struc-
tural arrangements of GARTfase and GARS domains
with respect to the central AIRS dimer (Figure 5). These
models are consistent with the experimental SAXS data
and demonstrate the putative seesaw-like domain arrange-
ments with GARTfase and AIRS domains of the dimer
organized in a linear fashion and GARS domains
arranged around AIRS dimer. Yet, due to the globular
shapes of GARTfase and GARS domains, the SAXS
data is not sensitive enough to differentiate among
speciﬁc domain orientations (Supplementary Figure S2).
This structural scenario implies that the linker regions
enable the sampling of a large conformational space
where domain crossing or swapping in the dimeric
molecule is also possible. Taking into account that the
molecular symmetry of the full-length enzyme is restricted
to the dimer forming, central AIRS domain, rigid-body
modeling was performed without constraints yet
preserving the symmetry of the AIRS dimer. This proced-
ure produced models, which reliably ﬁt the experimental
data (with an average goodness-of-ﬁt value of  =1.8;
Supplementary Figure S1). However, it is reasonable to
assume that no unique structure in solution would alone
account for the observed scattering behavior. A more real-
istic scenario will therefore encompass the presence of
many conformations in solution (including conformations
that may be more or less compact compared to those
shown in Figure 5) highlighting the dynamic nature of
this multi-domain macromolecule,
Li et al. (39) proposed a dimeric model of this
tri-functional enzyme, which is similar, yet not identical
to the experimental models presented here. Based on the
crystal structures it was estimated that the distance
between GARS and GARTfase domains is between 20
and 30A ˚ , whereas in our SAXS derived models it
appears to be in the range of 30–50A ˚ . It should be kept
in mind that there are many potential domain dispos-
itions, in particular the C-terminal GARTfase domain
appears to sample a large conformational space.
This behavior was also seen in SAXS experiments with a
protein construct consisting of only AIRS and GARTfase
domain (data not shown). This is not surprising since the
two domains are connected via a long linker that is
7316 Nucleic Acids Research, 2010, Vol.38, No. 20predicted to be disordered. The ﬂexibility of GARS and
GARTfase domains is not unexpected considering that the
tri-functional enzyme catalyzes three non-consecutive re-
actions of the pathway and the need for transferring
unstable substrate to GARS. Taken together this indicates
that this protein may function as a central gathering com-
ponent of the ‘purinosome’ (13). PRA substrate is
tunneled from PPAT to GARS catalyzing the second
step of the reaction. This interaction between PPAT and
GARS proposed earlier (7) is supported by the full-length
model derived from SAXS experiments as the PRA
binding crevice is directed away from the central AIRS
dimer. The product, GAR, is then transferred to the
C-terminal GARTfase. GARTfase is then able to pass
the product further to FGAMS, which is again able to
interact with both GART and the central AIRS dimer
catalyzing the following step of the reaction. One way to
speed up biosynthetic pathways is through multi-
functional enzymes or enzyme complexes that would
help accumulating intermediates at appropriate locations
concomitant with an increase of localized substrate
concentration.
A multi-domain enzyme assembly with a conformation-
al heterogeneity and ﬂexibility as seen in HsGART may
Figure 5. Overall conformations of full-length HsGART deduced from solution X-ray scattering (SAXS). Ten rigid-body models superimposed with
respect to the AIRS dimer thus highlighting the conformational space taken up by GARS (shades of blue) and GARTfase (shades of red) domains in
both monomers. The non-symmetry constrained rigid-body models are shown only. One of the models also includes the linker segments connecting
globular domains (yellow). (A) View along the AIRS (grey) dimer axis. (B) Orientation rotated 90  along y-axis.
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Cycling through a complex pathway such as the de novo
purine biosynthesis, which involves the interaction of
several enzymes with diverse functions, requires a
variable as well as an adaptable structural scaffold. The
conformational ﬂexibility appears not only to allow for
molecular associations but also dissociations taking place
efﬁciently. Benkovic and coworkers (13) coined the expres-
sion of ‘purinosome’ in view of a dynamic multi-enzyme
complex formed during de novo purine biosynthesis that is
regulated depending on cellular purine levels. The
conformation of full-length HsGART presented here
would portray a convenient structural framework for a
larger enzyme complex to be formed during catalysis.
Interestingly, a recent study (43) seems to suggest that
metabolite-dependent organization into large-scale
protein assemblies in response to cellular nutrient stress
may be a more general phenomenon in cell biology.
CONCLUSIONS
We have described the crystal structures of two enzymatic
domains of HsGART thus furnishing structures of all
domains of this tri-functional enzyme. Comparisons with
structures of homologous enzymes allowed us to clarify
potential substrate binding modes of the enzymes. Our
efforts to combine crystal structures with shape models
derived from SAXS successfully reveal the overall con-
formation of full-length HsGART in solution, but at the
same time demonstrate its dynamics and signiﬁcant struc-
tural ﬂexibility. This characteristic plasticity is likely to
have implications in view of the recently emerged
‘purinosome’ complex. The challenge will be to form
and preserve complexes of HsGART with various
proteins that are suitable for structural studies
investigating conformations of large complexes and inter-
actions between enzymatic reactions.
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